Breast cancer and aging: results of the U13 conference breast cancer panel
- 322 Downloads
Breast cancer is predominantly a disease of older women, yet there is a knowledge gap due to the persisting misalignment between the age distribution of women with breast cancer and the age distribution of participants in clinical trials. The purpose of this report is to state the U13 conference breast cancer panel’s recommendations regarding therapeutic clinical trials that will fill gaps in knowledge regarding the care of older patients with breast cancer. The U13 conference was a collaboration between the Cancer and Aging Research Group and the National Institute on Aging and the National Cancer Institute (NCI). Clinical trials should be developed for frail and vulnerable patients who would not enroll on the standard phase III trials, as well as efforts need to be made to increase enrollment of fit older patients on standard phase III trials. As a result of this conference, panel members are working with the NCI and cooperative groups to address these knowledge gaps. With the aging population and increasing incidence of breast cancer with age, it is essential to study the feasibility, toxicity, and efficacy of cancer therapy in this at-risk population.
KeywordsBreast cancer Aging Elderly
The study was supported by the U13 conference grant (U13 AG038151). The study sponsors were not involved in the writing of the article or the decision to submit it for publication. The authors were independent from study sponsors.
- 6.Owusu C, Hurria A, Muss H (2012) Adjuvant therapy for older women with early-stage breast cancer: treatment selection in a complex population. Am Soc Clin Oncol Educ Book 32:3–9Google Scholar
- 7.Minino AM, Murphy SL (2012) Death in the United States, 2010. NCHS Data Brief 1–8Google Scholar
- 9.van de Water W, Markopoulos C, van de Velde CJ et al (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307:590–597Google Scholar
- 12.Kimmick GG, Muss HB (2001) Systemic therapy for older women with breast cancer. Oncology (Williston Park) 15:280–291; discussion 291–292, 295–296, 299Google Scholar
- 14.Lichtman SM, Skirvin JA (2000) Pharmacology of antineoplastic agents in older cancer patients. Oncology (Williston Park) 14:1743–1755; discussion 1755, passimGoogle Scholar
- 17.Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRefGoogle Scholar
- 24.Blackwell KL MD, Gianni L, et al (2012) Primary results from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. 2012 ASCO Annual Meeting. Abstract LBA1. Presented June 3Google Scholar